{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-057769","form_type":"8-K","ticker":"ATNM","cik":"0001388320","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.321821+00:00","generated_at":"2026-06-28T10:34:25.754694+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Actinium shareholders re-elect two Class II directors; approve 2.75M share increase to 2019 Plan","bullets":["Sandesh Seth and Jeffrey W. Chell re-elected as Class II directors for term expiring at 2024 annual meeting.","Shareholders approved Second Amendment to 2019 Plan, increasing available shares by 2,750,000 to total 5,833,333.","Marcum LLP ratified as independent auditor for FY 2021 with 12,371,473 votes for.","Broker non-votes totaled 6,568,275 on director elections and plan amendment.","Annual meeting had 12,755,273 shares present; no other matters were voted on."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-057769","json":"https://secwatch.observer/filing/0001213900-21-057769.json","markdown":"https://secwatch.observer/filing/0001213900-21-057769.md","text":"https://secwatch.observer/filing/0001213900-21-057769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390021057769/0001213900-21-057769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390021057769/ea150278-8k_actiniumph.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:34:25.754694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}